Patents by Inventor Jarek Meller

Jarek Meller has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF ATTENUATING AN IMMUNE RESPONSE BY INHIBITION OF BFL1
    Publication number: 20230131243
    Abstract: The disclosure provides methods of modulating an immune response by inhibiting BFL1, and related methods for treating and preventing diseases and disorders characterized by inflammation, especially neutrophil induced inflammation.
    Type: Application
    Filed: December 19, 2022
    Publication date: April 27, 2023
    Applicant: CHILDREN'S HOSPITAL MEDICAL CENTER
    Inventors: David A. Hildeman, Andrew Herr, Suhas G. Kallapur, Jarek Meller, Alexander Thorman
  • Methods of attenuating an immune response by inhibition of BFL1
    Patent number: 11541073
    Abstract: The disclosure provides methods of modulating an immune response by inhibiting BFL1, and related methods for treating and preventing diseases and disorders characterized by inflammation, especially neutrophil induced inflammation.
    Type: Grant
    Filed: January 14, 2019
    Date of Patent: January 3, 2023
    Assignee: Children's Hospital Medical Center
    Inventors: David A. Hildeman, Andrew Herr, Suhas G. Kallapur, Jarek Meller, Alexander Thorman
  • COMPOUNDS USEFUL FOR INHIBITING BFL1 AND THEIR USE IN THERAPY
    Publication number: 20220249437
    Abstract: The disclosure provides compounds of Formula I and their use in methods of modulating an immune response by inhibiting BFL1, and related methods for treating and preventing diseases and disorders characterized by inflammation, especially neutrophil induced inflammation.
    Type: Application
    Filed: July 9, 2020
    Publication date: August 11, 2022
    Inventors: David A. Hildeman, Andrew Herr, Suhas G. Kallapur, Jarek Meller, Alexander Thorman
  • Diagnostic Tools and Treatments for Clear Cell Renal Cell Carcinoma
    Publication number: 20220136059
    Abstract: A method of diagnosing the likelihood of recurrence of clear cell renal cell carcinoma is provided. The method involves a) detecting the gene expression signatures of mitochondrial electron transport chain subunits, mitochondrial ribosomal proteins, major histocompatibility complex class II (MHC-II) proteins or combinations thereof in a kidney tumor tissue sample; and b) determining that the subject has an elevated risk of recurrence of clear cell renal cell carcinoma if the gene expression signatures include certain sequences. In another embodiment, the method uses copper levels to diagnose the likelihood of recurrence of clear cell renal cell carcinoma.
    Type: Application
    Filed: May 21, 2021
    Publication date: May 5, 2022
    Applicant: University of Cincinnati
    Inventors: Maria Franciszka Czyzyk-Krzeska, Julio Alberto Landero Figueroa, Jarek Meller, David Plas, Shuchi Gulati, Bhargav Vemuri, John Thomas Cunningham, IV
  • METHODS OF TREATMENT BY INHIBITION OF BFL1
    Publication number: 20210113604
    Abstract: The disclosure provides methods of modulating an immune response by inhibiting BFL1, and related methods for treating and preventing diseases and disorders characterized by inflammation, especially neutrophil induced inflammation.
    Type: Application
    Filed: January 14, 2019
    Publication date: April 22, 2021
    Inventors: David A. Hildeman, Andrew Herr, Suhas G. Kallapur, Jarek Meller, Alexander Thorman